<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/prognostic-value-of-the-quantitative-metabolic-volumetric-measurement-on-18f-fdg-pet-ct-in-stage-iv/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/prognostic-value-of-the-quantitative-metabolic-volumetric-measurement-on-18f-fdg-pet-ct-in-stage-iv/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2011-12-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T02:43:55+00:00","datePublished":"2011-12-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/prognostic-value-of-the-quantitative-metabolic-volumetric-measurement-on-18f-fdg-pet-ct-in-stage-iv/"},"url":"https://clinicaltree.github.io/posts/prognostic-value-of-the-quantitative-metabolic-volumetric-measurement-on-18f-fdg-pet-ct-in-stage-iv/"}</script><title>Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Prognostic Value of the Quantitative Metabolic Volumetric Measurement on 18F-FDG PET/CT in Stage IV Nonsurgical Small-cell Lung Cancer</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1325350800" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Dec 31, 2011 </em> </span> <span> Updated <em class="" data-ts="1681094635" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Shengri Liao MD</a> </em>, <em> <a href="">Bill C. Penney PhD</a> </em>, <em> <a href="">Hao Zhang MD PhD</a> </em>, <em> <a href="">Kenji Suzuki PhD</a> </em>, <em> <a href="">Yonglin Pu MD PhD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2767 words"> <em>15 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Stage IV non–small-cell lung cancer (NSCLC) consists of a heterogeneous group of patients with different prognoses. We assessed the prognostic value of baseline whole body tumor burden as measured by metabolic tumor volume (MTV), total lesion glycolysis (TLG), and standardized uptake values (SUV max and SUV mean ) of all tumors in nonsurgical patients with Stage IV NSCLC.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Ninety-two consecutive patients with newly diagnosed Stage IV NSCLC who had a pretreatment F-18 fludeoxyglucose positron emission tomography/computed tomography scan were retrospectively reviewed. The MTV, TLG, SUV mean , and SUV max of whole-body (WB) tumors were measured with the MIMvista workstation with manual adjustment.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>There was a statistically significant association between overall survival (OS) and ln(MTV)/ln(TLG) at the level of WB tumor burden (MTV WB ) and of primary tumor (MTV T ). The hazard ratio (HR) for a 1-unit increase of ln(MTV WB ) and ln(MTV T ) before and after adjusting for age and gender was 1.48/1.48 (both <em>P</em> &lt; .001) and 1.25/1.25 ( <em>P</em> = .006, .007), respectively. The HR for a 1-unit increase of ln(TLG WB ) and ln(TLG T ) before and after adjusting for age and gender was 1.37/1.37 (both <em>P</em> = .001) and 1.19/1.19 ( <em>P</em> = .001, .017), respectively. There was no statistically significant association between OS and ln(SUV max ) and ln(SUV mean ) at WB tumor burden, primary tumor, nodal metastasis, or distant metastasis ( <em>P</em> &gt; .05). There was low interobserver variability between two radiologists with concordance correlation coefficients of 0.90 for ln(MTV WB ) and greater than 0.90 for SUV maxWB , SUV meanWB , and ln(TLG WB ).</p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Baseline WB metabolic tumor burden, as measured with MTV and TLG, is a prognostic measurement in patients within Stage IV NSCLC with low interobserver variability. This study also suggests pretreatment MTV and TLG measurements may be used to further stratify patients with Stage IV NSCLC and are better prognostic measures than SUV max and SUV mean measurements.</p><p>Lung cancer is the most common cause of cancer death in the world and the second most common cancer in both men and women, and number one cause of cancer-related deaths in the United States. In the United States in 2010, 157,300 people were projected to die from lung cancer, which is more than the number of deaths from colon and rectal, breast, and prostate cancer combined . Non–small-cell lung cancer (NSCLC) comprises 80%–85% of all lung cancer cases .</p><p>Stage IV non–small-cell lung cancer (NSCLC) consists of a heterogeneous group of patients who are often treated with different modalities . Based on the comprehensive analysis of 67,149 patients with Stage IV NSCLC as defined by the 6th edition of the Union International Contra la Cancrum (UICC)/American Joint Committee on Cancer (AJCC) staging system for NSCLC enrolled in the Surveillance, Epidemiology, and End Results (SEER) program, the patients with distant metastasis have worse prognosis . The patients with tumor nodules on both sides of the chest have worse prognosis than those with separate ipsilateral tumor nodules in different lobes. The nodal status is a strong determinant of survival.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-recruitment"><span class="mr-2">Patient Recruitment</span><a href="#patient-recruitment" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="imaging-protocols"><span class="mr-2">Imaging Protocols</span><a href="#imaging-protocols" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="petct-imaging"><span class="mr-2">PET/CT imaging</span><a href="#petct-imaging" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="measurement-of-tumor-volume-on-petct"><span class="mr-2">Measurement of tumor volume on PET/CT</span><a href="#measurement-of-tumor-volume-on-petct" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/0_1s20S1076633211004430.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/0_1s20S1076633211004430.jpg" alt="Figure 1, Axial, sagittal, and coronal images from a positron emission tomography scan of a 57-year-old male with a new diagnosis of non–small-cell lung cancer, showing the measurements of standardized uptake value, metabolic tumor volume, and total lesion glycolysis with the MIMvista PETedge tool." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>The Distribution of the Gender and Age, and PET/CT Measurements with Corresponding Survival Probabilities in 92 Stage IV Nonsurgical Cases with Non–small-cell Lung Cancer</p><p>Mean ± SD Overall Survival Median (mo) 1-year (%) 2-year (%) Gender (n) Female (55) 9.09 41.82 21.82 Male (37) 9.68 37.84 13.51 Age 65.6 ± 10.81 &lt;Median (65) 56.69 ± 6.47 10.13 41.30 15.22 ≥Median 74.51 ± 5.67 8.24 39.13 21.74 SUV max SUV maxWB 10.99 ± 6.03 &lt;Median 70.1 ± 1.47 11.17 47.83 21.74 ≥Median 14.99 ± 6.23 8.9 32.61 15.22 SUV maxT 9.32 ± 436 &lt;Median 6.03 ± 1.91 10.37 45.65 19.57 ≥Median 12.62 ± 3.54 8.89 34.48 17.39 SUV maxN 5.81 ± 5.64 &lt;Median 2.29 ± 2.02 11.67 50.00 23.91 ≥Median 9.32 ± 5.92 7.36 30.43 13.04 SUV maxM 5.88 ± 5.94 &lt;Median 2.03 ± 1.93 10.25 43.48 23.91 ≥Median 9.73 ± 6.11 8.06 36.96 13.04 SUV mean SUV meanWB 3.78 ± 1.48 &lt;Median 2.88 ± 0.44 9.12 39.13 15.22 ≥Median 4.68 ± 1.59 10.13 41.30 21.74 SUV meanT 3.67 ± 1.19 &lt;Median 2.75 ± 0.63 9.42 43.48 17.39 ≥Median 4.58 ± 0.87 9.26 36.96 19.57 SUV meanN 4.15 ± 6.39 &lt;Median 2.48 ± 0.46 9.68 37.84 13.51 ≥Median 5.83 ± 8.76 8.12 41.82 21.82 SUV meanM 3.13 ± 1.51 &lt;Median 2.21 ± 0.60 8.69 35.14 13.51 ≥Median 4.07 ± 1.58 10.12 43.64 21.82 MTV MTV WB 248.21 ± 251.95 &lt;Median 72.02 ± 44.50 13.89 58.57 32.61 ≥Median 424.41 ± 250.83 6.51 21.74 4.35 MTV T 142.95 ± 197.29 &lt;Median 22.56 ± 16.40 12.72 52.17 28.26 ≥Median 263.34 ± 220.93 6.8 28.26 8.7 MTV N 40.53 ± 63.92 &lt;Median 3.85 ± 4.23 10.84 47.83 21.74 ≥Median 77.20 ± 74.13 7.36 32.61 15.22 MTV M 62.32 ± 123.92 &lt;Median 3.49 ± 4.01 10.7 43.48 23.91 ≥Median 121.14 ± 154.79 8.06 36.96 13.04 TLG TLG WB 968.4 ± 1029.48 &lt;Median 255.61 ± 174.89 13.62 56.52 32.61 ≥Median 1681.19 ± 1036.30 6.8 23.91 4.35 TLG T 573.29 ± 810.85 &lt;Median 77.04 ± 59.54 13.35 54.35 30.43 ≥Median 1069.54 ± 906.95 6.8 26.09 6.52 TLG N 157.12 ± 291.79 &lt;Median 11.21 ± 13.71 11.67 50.00 21.74 ≥Median 303.04 ± 358.41 7.07 30.43 15.22 TLG M 229.56 ± 501.57 &lt;Median 8.59 ± 11.02 10.25 41.30 23.91 ≥Median 450.53 ± 639.37 9.12 39.13 13.04</p><p>CI, confidence interval; HR, hazard ratio; mo, months; MTV, metabolic tumor volume (mL); MTV WB , MTV of whole body tumor (a median of 154.35 mL); MTV T , MTV of primary tumor (a median of 56.57 mL); MTV N , MTV of nodal metastasis (a median of 13.16 mL); MTV M , MTV of distant metastasis (a median of 12.46 mL); OS, overall survival; SD, standard deviation; SUV max , maximum standardized uptake value; SUV maxWB , SUV max of whole body tumor (with a median of 9.28); SUV maxT , SUV max of primary tumor (a median of 8.67); SUV maxN , SUV max of nodal metastasis (a median of 5.47); SUV maxM , SUV max of distant metastasis (a median of 4.99); SUV mean , mean standardized uptake value; SUV meanWB , SUV mean of whole body tumor (a median of 3.43); SUV meanT , SUV mean of primary tumor (a median of 3.51); SUV mean , SUV mean of nodal metastasis (a median of 3.04); SUV meanM , SUV mean of distant metastasis (a median of 2.94); TLG, total lesion glycolysis (SUV*mL); TLG WB , TLG of whole body tumor (a median of 574.65 SUV∗mL); TLG T , TLG of primary tumor (a median of 214.13 SUV∗mL); TLG N , TLG of nodal metastasis (a median of 48.95 SUV∗mL); TLG M , TLG of distant metastasis (a median of 34.26 SUV∗mL).</p><p>Table 2</p><p>The Association of Overall Survival (OS) with Age, Gender, and PET/CT Measurements in 92 Stage IV Nonsurgical Cases with Non–small-cell Lung Cancer</p><p>Univariate Analysis Multivariate Analysis ∗ HR (95% CI)<em>P</em> Value HR (95% CI)<em>P</em> Value Gender Male vs. female 1.24 (0.79–1.96) .349 Age (y) &lt;65.6 vs. ≥65.6 0.996 (0.98–1.02) .712 SUV max ln(SUV maxWB ) 1.27 (082–1.99) .28 1.24 (0.80–1.95) .335 ln(SUV maxT ) 1.35 (0.92–1.99) .13 1.35 (0.91–1.98) .134 ln(SUV maxN ) 1.00 (0.63–1.61) .98 0.98 (0.61–1.57) .918 ln(SUV maxM ) 1.16 (0.77–1.73) .48 1.17 (0.77–1.77) .464 SUV mean ln(SUV meanWB ) 1.14 (0.57–2.25) .72 1.07 (0.53–2.15) .85 ln(SUV meanT ) 1.20 (0.70–2.06) .50 1.18 (0.69–2.01) .554 ln(SUV mean ) 1.34 (0.81–2.20) .26 1.26 (0.75–2.13) .385 ln(SUV meanM ) 1.00 (0.56–1.81) .99 0.99 (0.55–1.80) .99 MTV ln(MTV WB ) 1.48 (1.20–1.82) &lt;.001 1.48 (1.19–1.84) &lt;.001 ln(MTV T ) 1.25 (1.07–1.47) .006 1.25 (1.06–1.47) .007 ln(MTV N) 1.21 (0.99–1.47) .06 1.19 (0.97–1.46) .09 ln(MTV M ) 1.06 (0.90–1.25) .48 1.07 (0.90–1.27) .42 TLG ln(TLG WB ) 1.37 (1.13–1.65) .001 1.37 (1.13–1.66) .001 ln(TLG T ) 1.19 (1.04–1.37) .01 1.19 (1.03–1.36) .017 ln(TLG N ) 1.17 (0.98–1.39) .08 1.15 (0.96–1.38) .118 ln(TLG M ) 1.04 (0.91–1.20) .55 1.05 (0.91–1.22) .495</p><p>CI, confidence interval; HR, hazard ratio; ln, natural log transformation was performed before Cox regression analysis. See Table 1 for other abbreviations.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 3</p><p>Association of Overall Survival (OS) with Gender, Age, and PET/CT Measurements in 79 Nonsurgical Patients in Stage IV with Non–small-cell Lung Cancer</p><p>Univariate Analysis Multivariate Analysis ∗ HR (95% CI)<em>P</em> Value HR (95% CI)<em>P</em> Value Gender Female Reference .476 Male 1.20 (0.73–1.98) Age 0.99 (0.97–1.01) .388 SUV max ln(SUV maxWB ) 1.14 (0.70–1.86) .600 1.11 (0.68–1.83) .668 ln(SUVmaxT) 1.28 (0.85–1.95) .241 1.28 (0.85–1.95) .240 ln(SUVmaxN) 0.98 (0.60–1.62) .949 0.96 (0.58–1.59) .877 ln(SUV max M) 1.00 (0.63–1.58) .983 0.96 (0.60–1.54) .862 SUV mean ln(SUV meanWB ) 1.00 (0.47–2.12) .992 0.97 (0.46–2.06) .939 ln(SUV meanT ) 1.13 (0.64–1.98) .673 1.11 (0.64–1.95) .707 ln(SUV meanN ) 1.18 (0.65–2.15) .584 1.12 (0.61–2.07) .717 ln(SUV meanM ) 0.83 (0.44–1.55) .552 0.80 (0.43–1.50) .489 MTV ln(MTV WB ) 1.41 (1.11–1.78) .005 1.39 (1.09–1.78) .009 ln(MTV T ) 1.20 (1.00–1.44) .045 1.19 (0.99–1.42) .063 ln(MTV N ) 1.16 (0.94–1.44) .167 1.15 (0.92–1.42) .211 ln(MTV M ) 1.00 (0.84–1.20) .987 0.98 (0.81–1.19) .842 TLG ln(TLG WB ) 1.30 (1.05–1.60) .014 1.28 (1.03–1.59) .023 ln(TLG T ) 1.15 (0.99–1.33) .078 1.14 (0.97–1.32) .104 ln(TLG N ) 1.12 (0.93–1.35) .228 1.11 (0.92–1.34) .289 ln(TLG M ) 0.99 (0.85–1.15) .898 0.97 (0.82–1.15) .729</p><p>Abbreviations as in Tables 1 and 2 .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/1_1s20S1076633211004430.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/1_1s20S1076633211004430.jpg" alt="Figure 2, Kaplan-Meier curves of overall survival after baseline positron emission tomography (PET)/computed tomography grouped according to PET measurements in 92 nonsurgical patients with stage IV non–small-cell lung cancer show the association of the natural logarithm of whole-body metabolic tumor volume [ln(MTV WB )] with cumulative survival. The dashed lines indicate the group with values less than the median and the solid lines are the group with values greater than or equal to the median of the PET measurements." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/2_1s20S1076633211004430.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/2_1s20S1076633211004430.jpg" alt="Figure 3, Kaplan-Meier curves of overall survival after baseline positron emission tomography (PET)/computed tomography grouped according to PET measurements in 92 nonsurgical patients with stage IV non–small-cell lung cancer show the association of the natural logarithm of whole-body total lesion glycolysis [ln(TLG WB )] and cumulative survival. The dashed lines indicate the group with values less than the median and the solid lines are the group with values greater than or equal to the median of the PET measurements." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/3_1s20S1076633211004430.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/3_1s20S1076633211004430.jpg" alt="Figure 4, Kaplan-Meier curves of overall survival after baseline positron emission tomography (PET)/computed tomography grouped according to PET measurements in 92 nonsurgical patients with stage IV non–small-cell lung cancer show the association of the natural logarithm of whole-body maximum standardized uptake value [ln(SUV maxWB )] and cumulative survival. The dashed lines indicate the group with values less than the median and the solid lines are the group with values greater than or equal to the median of the PET measurements." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/4_1s20S1076633211004430.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/PrognosticValueoftheQuantitativeMetabolicVolumetricMeasurementon18FFDGPETCTinStageIVNonsurgicalSmallcellLungCancer/4_1s20S1076633211004430.jpg" alt="Figure 5, Kaplan-Meier curves of overall survival after baseline positron emission tomography (PET)/computed tomography grouped according to PET measurements in 92 nonsurgical patients with stage IV non–small-cell lung cancer show the association of the natural logarithm of whole-body mean standardized uptake value [ln(SUV meanWB )] and cumulative survival. The dashed lines indicate the group with values less than the median and the solid lines are the group with values greater than or equal to the median of the PET measurements." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusion-1"><span class="mr-2">Conclusion</span><a href="#conclusion-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Parkin D.M., Bray F.I., Devesa S.S.: Cancer burden in the year 2000: the global picture. Eur J Cancer 2001; 37: pp. S4-S66.</p><li><p>2. Jemal A., Siegel R., Xu J., et. al.: Cancer statistics, 2010. CA Cancer J Clinicians 2010; 60: pp. 277-300.</p><li><p>3. Traynor A.M., Schiller J.H.: Systemic treatment of advanced non-small cell lung cancer. Drugs of Today 2004; 40: pp. 697-710.</p><li><p>4. UyBico S.J., Wu C.C., Suh R.D., et. al.: Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 2010; 30: pp. 1163-1181.</p><li><p>5. American Joint Committee on Cancer: AJCC Cancer Staging Manual.6th ed.2002.SpringerNew York, NY</p><li><p>6. William W.N., Lin H.Y., Lee J.J., et. al.: Revisiting stage IIIB and IV non-small cell lung cancer: analysis of the surveillance, epidemiology, and end results data. Chest 2009; 136: pp. 701-709.</p><li><p>7. Lee P., Weerasuriya D.K., Lavori P.W., et. al.: Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys 2007; 69: pp. 328-333.</p><li><p>8. La T.H., Filion E.J., Turnbull B.B., et. al.: Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys Physics 2009; 74: pp. 1335-1341.</p><li><p>9. Larson S.M., Erdi Y., Akhurst T., et. al.: Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging: the visual response score and the change in total lesion glycolysis. Clin Pos Imaging 1999; 2: pp. 159-171.</p><li><p>10. Berkowitz A., Basua S., Srinivasa S., et. al.: Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nuc Med Commun 2008; 29: pp. 521-526.</p><li><p>11. Roedl J.B., Colen R.R., Holalkere N.S., et. al.: Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol 2008; 89: pp. 278-286.</p><li><p>12. Zhu D., Ma T., Niu Z., et. al.: Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer 2011; 73: pp. 332-337.</p><li><p>13. Seol Y.M., Kwon B.R., Song M.K., et. al.: Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemoradiation therapy. Acta Oncol 2010; 49: pp. 201-208.</p><li><p>14. Xie P., Yue J.B., Zhao H.X., et. al.: Prognostic value of 18-F FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2010; 136: pp. 883-889.</p><li><p>15. Man K.C., Jeong H.-S., Sang G.P., et. al.: Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 2009; 15: pp. 5861-5868.</p><li><p>16. Hyun S.H., Choi J.Y., Shim Y.M., et. al.: Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 2010; 17: pp. 115-122.</p><li><p>17. Wang W., Larson S.M., Fazzari M., et. al.: Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85: pp. 1107-1113.</p><li><p>18. Bradley J.D., Ieumwananonthachai N., Purdy J.A., et. al.: Gross tumor volume, critical prognostic factor in patients treated with three-dimensional conformal radiation therapy for non–small cell lung carcinoma. Int J Radiat Oncol Biol Phys 2002; 52: pp. 49-57.</p><li><p>19. Socinski M.A., Morris D.E., Masters G.A., et. al.: Chemotherapeutic management of stage IV non-small cell lung cancer. Chest 2003; 123: pp. 226S-243S.</p><li><p>20. Doi K.: Computer-aided diagnosis in medical imaging: historical review, current status and future potential. Comp Med Imaging Graphics 2007; 31: pp. 198-211.</p><li><p>21. Shankar L.K., Hoffman J.M., Bacharach S., et. al.: Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006; 47: pp. 1059-1066.</p><li><p>22. Werner-Wasik M., Nelson A.D., Choi W., et. al.: What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 2011 Apr 28; [Epub ahead of print]</p><li><p>23. Cox D.R.: Regression models and life-tables (with discussion). J Royal Stat Soc Series B 1972; 34: pp. 187-220.</p><li><p>24. Kaplan E.L., Meier P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: pp. 457-481.</p><li><p>25. Mountain C.F.: Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: pp. 1710-1717.</p><li><p>26. Adebonojo S.A., Bowser A.N., Moritz D.M., et. al.: Impact of revised stage classification of lung cancer on survival: a military experience. Chest 1999; 115: pp. 1507-1513.</p><li><p>27. van Rens M.T., de la Riviere A.B., Elbers H.R., et. al.: Prognostic assessment of 2,361 patients who underwent pulmonary resection for non–small cell lung cancer, stage I, II, and IIIA. Chest 2000; 117: pp. 374-379.</p><li><p>28. Borst G.R., Belderbos J.S., Boellaard R., et. al.: Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur J Cancer 2005; 41: pp. 1533-1541.</p><li><p>29. Davies A., Tan C., Paschalides C., et. al.: FDG-PET maximum standardised uptake value is associated with variation in survival: Analysis of 498 lung cancer patients. Lung Cancer 2007; 55: pp. 75-78.</p><li><p>30. van Baardwijk A., Dooms C., van Suylen R.J., et. al.: The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007; 43: pp. 1392-1398.</p><li><p>31. Lee K.H., Lee S.H., Kim D.W., et. al.: High fluorodeoxyglucose uptake on positron emission tomography in patients with advanced non-small cell lung cancer on platinum-based combination chemotherapy. Clin Cancer Res 2006; 12: pp. 4232-4236.</p><li><p>32. Wahl R.L., Jacene H., Kasamon Y., et. al.: From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: pp. 122S-150S.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-19/'>Volume 19</a>, <a href='/categories/issue-1/'>Issue 1</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Prognostic%20Value%20of%20the%20Quantitative%20Metabolic%20Volumetric%20Measurement%20on%2018F-FDG%20PET/CT%20in%20Stage%20IV%20Nonsurgical%20Small-cell%20Lung%20Cancer%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fprognostic-value-of-the-quantitative-metabolic-volumetric-measurement-on-18f-fdg-pet-ct-in-stage-iv%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Prognostic%20Value%20of%20the%20Quantitative%20Metabolic%20Volumetric%20Measurement%20on%2018F-FDG%20PET/CT%20in%20Stage%20IV%20Nonsurgical%20Small-cell%20Lung%20Cancer%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fprognostic-value-of-the-quantitative-metabolic-volumetric-measurement-on-18f-fdg-pet-ct-in-stage-iv%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fprognostic-value-of-the-quantitative-metabolic-volumetric-measurement-on-18f-fdg-pet-ct-in-stage-iv%2F&text=Prognostic%20Value%20of%20the%20Quantitative%20Metabolic%20Volumetric%20Measurement%20on%2018F-FDG%20PET/CT%20in%20Stage%20IV%20Nonsurgical%20Small-cell%20Lung%20Cancer%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/a-semi-automatic-algorithm-for-determining-the-demyelination-load-in-metachromatic-leukodystrophy/"><div class="card-body"> <em class="small" data-ts="1325350800" data-df="ll" > Dec 31, 2011 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>A Semi-Automatic Algorithm for Determining the Demyelination Load in Metachromatic Leukodystrophy</h3><div class="text-muted small"><p> Rationale and Objectives Metachromatic leukodystrophy is a lysosomal storage disorder leading to progressive demyelination of brain white matter. This is sensitively detected using magnetic resona...</p></div></div></a></div><div class="card"> <a href="/posts/breast-cancer-risk-assessment-in-64-659-women-at-a-single-high-volume-mammography-clinic/"><div class="card-body"> <em class="small" data-ts="1325350800" data-df="ll" > Dec 31, 2011 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Breast Cancer Risk Assessment in 64,659 Women at a Single High-Volume Mammography Clinic</h3><div class="text-muted small"><p> Rationale and Objectives In 2007, the American Cancer Society (ACS) recommended that women at elevated risk of breast cancer be screened with breast magnetic resonance imaging (MRI) as an adjunct ...</p></div></div></a></div><div class="card"> <a href="/posts/can-whole-body-low-dose-multidetector-ct-exclude-the-presence-of-myeloma-bone-disease-in-patients-wi/"><div class="card-body"> <em class="small" data-ts="1325350800" data-df="ll" > Dec 31, 2011 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Can Whole-body Low-dose Multidetector CT Exclude the Presence of Myeloma Bone Disease in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS)?</h3><div class="text-muted small"><p> Rationale and Objectives To determine the benefit of using whole-body low-dose computed tomography (WBLD-CT) in patients with monoclonal gammopathy of undetermined significance (MGUS) for exclusio...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/partnering-with-engineers-to-identify-and-empirically-evaluate-delays-in-magnetic-resonance-imaging/" class="btn btn-outline-primary" prompt="Older"><p>Partnering with Engineers to Identify and Empirically Evaluate Delays in Magnetic Resonance Imaging</p></a> <a href="/posts/promotion-as-a-clinician-educator-in-academic-radiology-departments/" class="btn btn-outline-primary" prompt="Newer"><p>Promotion as a Clinician Educator in Academic Radiology Departments</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
